JP2016128399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016128399A5 JP2016128399A5 JP2015118495A JP2015118495A JP2016128399A5 JP 2016128399 A5 JP2016128399 A5 JP 2016128399A5 JP 2015118495 A JP2015118495 A JP 2015118495A JP 2015118495 A JP2015118495 A JP 2015118495A JP 2016128399 A5 JP2016128399 A5 JP 2016128399A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- lipophilic
- amino acids
- group
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUE15793746A HUE051268T2 (hu) | 2014-12-11 | 2015-11-04 | Immunellenõrzõpont-gátló kombinációk |
| US15/534,800 US11083774B2 (en) | 2014-12-11 | 2015-11-04 | Immune checkpoint inhibitor combinations |
| ES15793746T ES2819282T3 (es) | 2014-12-11 | 2015-11-04 | Combinaciones de inhibidores de puntos de control inmunitarios |
| PCT/EP2015/075722 WO2016091487A1 (en) | 2014-12-11 | 2015-11-04 | Immune checkpoint inhibitor combinations |
| EP15793746.7A EP3230318B1 (en) | 2014-12-11 | 2015-11-04 | Immune checkpoint inhibitor combinations |
| AU2015359881A AU2015359881B2 (en) | 2014-12-11 | 2015-11-04 | Immune checkpoint inhibitor combinations |
| PL15793746T PL3230318T3 (pl) | 2014-12-11 | 2015-11-04 | Kombinacje inhibitora immunologicznego punktu kontrolnego |
| DK15793746.7T DK3230318T3 (da) | 2014-12-11 | 2015-11-04 | Immune checkpoint-inhibitor-kombinationer |
| LTEP15793746.7T LT3230318T (lt) | 2014-12-11 | 2015-11-04 | Imuninės kontrolės taško inhibitorių kombinacijos |
| PT157937467T PT3230318T (pt) | 2014-12-11 | 2015-11-04 | Combinações de inibidores de pontos de controlo imunitários |
| AU2019203199A AU2019203199B2 (en) | 2014-12-11 | 2019-05-07 | Immune checkpoint inhibitor combinations |
| AU2021204356A AU2021204356B2 (en) | 2014-12-11 | 2021-06-25 | Immune checkpoint inhibitor combinations |
| US17/366,463 US20230201305A9 (en) | 2014-12-11 | 2021-07-02 | Immune checkpoint inhibitor combinations |
| US18/598,719 US12239686B2 (en) | 2014-12-11 | 2024-03-07 | Immune checkpoint inhibitor combinations |
| US19/022,157 US20250332217A1 (en) | 2014-12-11 | 2025-01-15 | Immune checkpoint inhibitor combinations |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422084 | 2014-12-11 | ||
| GB1422084.2 | 2014-12-11 | ||
| GB1506127.8 | 2015-04-10 | ||
| GBGB1506127.8A GB201506127D0 (en) | 2015-04-10 | 2015-04-10 | Immune checkpoint inhibitor combinations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016128399A JP2016128399A (ja) | 2016-07-14 |
| JP2016128399A5 true JP2016128399A5 (enExample) | 2018-05-10 |
| JP6767096B2 JP6767096B2 (ja) | 2020-10-14 |
Family
ID=56384106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015118495A Active JP6767096B2 (ja) | 2014-12-11 | 2015-06-11 | 免疫チェックポイント阻害剤の組み合わせ |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11083774B2 (enExample) |
| EP (1) | EP3230318B1 (enExample) |
| JP (1) | JP6767096B2 (enExample) |
| AU (3) | AU2015359881B2 (enExample) |
| DK (1) | DK3230318T3 (enExample) |
| ES (1) | ES2819282T3 (enExample) |
| HU (1) | HUE051268T2 (enExample) |
| LT (1) | LT3230318T (enExample) |
| PL (1) | PL3230318T3 (enExample) |
| PT (1) | PT3230318T (enExample) |
| WO (1) | WO2016091487A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6767096B2 (ja) * | 2014-12-11 | 2020-10-14 | リティックス バイオファーマ エイエス | 免疫チェックポイント阻害剤の組み合わせ |
| EP3560513A4 (en) | 2016-12-26 | 2020-10-14 | National University Corporation Kobe University | ANTICANCER THERAPY USING A COMBINATION OF AN ORAL TUMOR VACCINE AND AN IMMUNOSUPPRESSION INHIBITOR |
| WO2018188761A1 (en) * | 2017-04-13 | 2018-10-18 | Lytix Biopharma As | Method of reducing population size of tregs and/or mdscs |
| CN119868398A (zh) | 2018-06-14 | 2025-04-25 | 株式会社明治 | 用于促进免疫检查点抑制疗法的组合物 |
| BR112021022659A2 (pt) | 2019-05-15 | 2022-03-29 | Chemocentryx Inc | Compostos triarílicos para o tratamento de doenças pd-l1 |
| KR102841588B1 (ko) | 2019-06-20 | 2025-08-01 | 케모센트릭스, 인크. | Pd-l1 질환의 치료를 위한 화합물 |
| CN110317245B (zh) * | 2019-08-02 | 2021-04-09 | 郑州大学 | Lag-3蛋白亲和环肽及其应用 |
| ES3068390T3 (en) | 2019-10-16 | 2026-05-29 | Chemocentryx Inc | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases |
| AU2020368392B2 (en) | 2019-10-16 | 2026-01-08 | Chemocentryx, Inc. | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases |
| US20230037966A1 (en) * | 2020-01-07 | 2023-02-09 | The Trustees Of The University Of Pennsylvania | Source specific exosomes for determining avoidance of cancer treatment and avoidance of checkpoint inhibitor therapies |
| AU2023413685A1 (en) | 2022-12-20 | 2025-06-19 | Lytix Biopharma As | Compositions comprising an oncolytic peptide and chitosan |
| EP4637799A1 (en) | 2022-12-20 | 2025-10-29 | Lytix Biopharma AS | Medical products containing an aqueous formulation of a peptide |
| CN117402828A (zh) * | 2023-04-13 | 2024-01-16 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种人肺癌脑转移瘤细胞系及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811097A (en) * | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| CA2328507A1 (en) | 1998-05-04 | 1999-11-11 | Thomas Jefferson University | Use of a composition comprising tumor cells or tumor cell extracts for inducing an anti-tumor response in a mammalian patient |
| GB0605685D0 (en) * | 2006-03-21 | 2006-05-03 | Lytix Biopharma As | Inhibition of tumour growth |
| DE60334303D1 (de) * | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| GB0821616D0 (en) | 2008-11-26 | 2008-12-31 | Lytix Biopharma As | Compounds |
| WO2011041613A2 (en) * | 2009-09-30 | 2011-04-07 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| US9410206B2 (en) * | 2011-11-30 | 2016-08-09 | John Wayne Cancer Institute | Long noncoding RNA (lncRNA) as a biomarker and therapeutic marker in cancer |
| US10202454B2 (en) * | 2013-10-25 | 2019-02-12 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
| EP3107576A4 (en) * | 2014-02-21 | 2017-09-06 | Abbvie Stemcentrx LLC | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| MX2017007535A (es) * | 2014-12-09 | 2017-08-10 | Merck Sharp & Dohme | Sistema y metodos para derivar biomarcadores de firmas geneticas de la respuesta a antagonistas de muerte programada 1 (pd-1). |
| JP6767096B2 (ja) * | 2014-12-11 | 2020-10-14 | リティックス バイオファーマ エイエス | 免疫チェックポイント阻害剤の組み合わせ |
| JP6813258B2 (ja) * | 2014-12-11 | 2021-01-13 | リティックス バイオファーマ エイエス | 化学療法の組み合わせ |
-
2015
- 2015-06-11 JP JP2015118495A patent/JP6767096B2/ja active Active
- 2015-11-04 EP EP15793746.7A patent/EP3230318B1/en active Active
- 2015-11-04 US US15/534,800 patent/US11083774B2/en active Active
- 2015-11-04 PL PL15793746T patent/PL3230318T3/pl unknown
- 2015-11-04 PT PT157937467T patent/PT3230318T/pt unknown
- 2015-11-04 ES ES15793746T patent/ES2819282T3/es active Active
- 2015-11-04 DK DK15793746.7T patent/DK3230318T3/da active
- 2015-11-04 LT LTEP15793746.7T patent/LT3230318T/lt unknown
- 2015-11-04 WO PCT/EP2015/075722 patent/WO2016091487A1/en not_active Ceased
- 2015-11-04 HU HUE15793746A patent/HUE051268T2/hu unknown
- 2015-11-04 AU AU2015359881A patent/AU2015359881B2/en active Active
-
2019
- 2019-05-07 AU AU2019203199A patent/AU2019203199B2/en active Active
-
2021
- 2021-06-25 AU AU2021204356A patent/AU2021204356B2/en active Active
- 2021-07-02 US US17/366,463 patent/US20230201305A9/en not_active Abandoned
-
2024
- 2024-03-07 US US18/598,719 patent/US12239686B2/en active Active
-
2025
- 2025-01-15 US US19/022,157 patent/US20250332217A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104853776B (zh) | 免疫应答的增强 | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| JP2018501197A5 (enExample) | ||
| MX2024004332A (es) | Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos. | |
| JP2015504871A5 (enExample) | ||
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| JP2016527286A5 (enExample) | ||
| JP2016539096A5 (enExample) | ||
| CY1118947T1 (el) | Ασυμμετρες ουριες και ιατρικες χρησεις αυτων | |
| JP2017503014A5 (enExample) | ||
| JP2017508744A5 (enExample) | ||
| AU2021203564B2 (en) | Compositions comprising naphthyridine derivatives and aluminium adjuvant for use in treating solid tumors | |
| BR112018001534A2 (pt) | inibidor de isocitrato desidrogenase idh1 r132h mutante | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| JP2025185043A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 | |
| EA202090959A1 (ru) | Аминзамещенные гетероциклические соединения в качестве ингибиторов ehmt2, их соли и способы их синтеза | |
| AU2018360386A1 (en) | Dual inhibitors of TIM-3 and PD-1 pathways | |
| EA201300436A1 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| JP2022518232A5 (enExample) | ||
| RU2011123700A (ru) | Нонапептид с противоопухолевой активностью | |
| TWI771372B (zh) | Wnt抑制劑與抗-pd-1抗體分子組合之給藥方案 | |
| JP2018519324A5 (enExample) | ||
| CY1120852T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει ιβουπροφαινη, τραμαδολη και ενα βασικο αμινοξυ, μεθοδος παρασκευης αυτης και χρηση της ιδιας | |
| FI3463436T3 (fi) | Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää | |
| EP3209328B1 (en) | Inhibitors of lactate transporters for use in the treatment of inflammatory diseases |